We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sepsis Test Demonstrates Clinical Utility in Critically Ill Heterogeneous Patient Populations

By LabMedica International staff writers
Posted on 18 Oct 2024

Sepsis is the primary cause of death in hospitals, resulting in more fatalities than any other condition due to its rapid onset and the challenges associated with early detection. More...

If not identified or treated promptly, sepsis can lead to tissue damage, organ failure, permanent disability, and often death. Physicians around the world face difficulties in quickly and reliably diagnosing sepsis due to inadequate diagnostic tools. A patient's pre-existing medical conditions can influence the body's immune response to infection as well as the clinical parameters utilized for diagnosing sepsis. The effectiveness of a diagnostic test for sepsis relies on its capability to distinguish between sepsis and systemic inflammatory response syndrome (SIRS) in various critically ill patient populations, including immunocompromised individuals and those with cancer. Now, a sample-to-answer, cartridge-based host response molecular test for sepsis has shown consistent performance in differentiating sepsis from SIRS, regardless of demographics or the presence of medical conditions.

Immunexpress’ (Seattle, WA, USA) SeptiCyte RAPID is a sample-to-answer, cartridge-based host response molecular test for sepsis that utilizes reverse transcription polymerase chain reaction (RT-PCR) to quantify the relative expression levels of host response genes extracted from whole blood. SeptiCyte RAPID is designed to be used alongside clinical assessments, vital signs, and laboratory findings to help differentiate infection-positive (sepsis) from infection-negative SIRS in patients exhibiting escalating signs and symptoms of critical illness. The test generates a score (SeptiScore) that categorizes results into four distinct interpretation bands based on the increasing likelihood of sepsis. SeptiCyte RAPID is intended for in-vitro diagnostic use and operates on the Biocartis Idylla Platform.

In a study published in the Journal of Clinical Medicine, SeptiCyte RAPID demonstrated its ability to effectively differentiate between sepsis and SIRS across various races, differing medical conditions, treatment regimens, and sources of infection, as well as classify patients into distinct phenotypes based on clinical severity. Identifying the phenotypes of complex sepsis patients is crucial for determining the most appropriate and individualized treatments. The study demonstrated that the performance of SeptiCyte RAPID remained largely unaffected by key variables associated with patient heterogeneity, including differences among racial groups and underlying disease states. The test successfully identified septic shock in both Black and White patients.

No significant performance differences were observed based on the presence or absence of conditions such as hyperglycemia, impaired immunity, hypertension, cardiovascular disease, kidney disease, cancer, or obesity. Using unsupervised learning methods, two to three distinct patient subgroups were identified among those with sepsis. One subgroup was primarily composed of patients displaying more severe sepsis, including septic shock. The study found two to three distinct patient subgroups within the entire cohort of sepsis or SIRS patients. SeptiCyte RAPID consistently demonstrated strong performance across subgroups in both sepsis and SIRS patients. SeptiCyte RAPID is CE Marked as a near-patient sample-to-answer test in European Union (EU) member countries and those aligned with the EU IVD Directive (98/79/EC). As of November 2021, SeptiCyte RAPID has also received FDA clearance for use in hospitalized patients suspected of having sepsis.

Related Links:
Immunexpress
Biocartis
 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.